Do antagonists of angiotensin II AT1 receptors protect the kidney?;Les antagonistes des recepteurs AT1 de l'angiotensine II sont-ils nephroprotecteurs?

Archives des Maladies du Coeur et des Vaisseaux

Volumn 92, Issue 7, 1999, Pages 903-907

  Deray, G ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR;

CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DISEASE; META ANALYSIS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; ANIMAL; CONTROLLED CLINICAL TRIAL; DISEASE MODEL; DRUG ANTAGONISM; HYPERTENSION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CONTROLLED CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION; KIDNEY DISEASES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0032781247     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-30.
2. Cattran DC, Grenwood C, Ritchie S. The long-term benefit of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy. A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994; 23: 247-54.
3. Lewis EJ, Hunsiker IG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
4. Crary G, Swan S, O'Donnel M, Kasiske B, Katz S, Keane W. The angiotensin II receptor antagonist Losartan reduces blood pressure but not renal injury in obese zucker rats. J Am Soc Nephrol 1995; 6: 1295-9.
5. Hytchinson F, Webster S. Effect of angiotensin II receptor antagonist on albuminuria and renal function in passive Heymann nephritis. Am J Physiol 1992; 263: F 311-F 318.
6. Ziai F, Nagano H, Azuma JL et al. Renal protective effects of TCV 116 in experimental chronic renal allografts failure. (abstract). J Am Soc Nephrol 1996; 7: 1900.
7. Heller J, Kramer HJ, Cervenka L, Hellerova S. Losartan protects the rat kidney from ischemic injury. Kidney Int 1996; 49 (suppl. 55): S 113-S 114.
8. MacKenzie HS, Troy JL, Brenner BM. Effects of combination therapy with Enalapril (Enal) and Losartan (Los) on the rate of progression of experimental renal injury in rats (abstract). J Ann Soc nephrol 1996; 7: 1860.
9. Hayakawa H, Coffee K, Guerra J, Raij L. Cardio-renal protection by the angiotensin II blocker Irbesartan in salt-sensitive hypertension (abstract). J Hypertension 1997; 15 (S 4): S 90.
10. Junaid A, Hosteller TH. Effects of angiotensin II (AII) antagonism vs control of systemic hypertension on remnant kidney TGF-b1. (abstract). J Am Soc Nephrol 1996; 7: 1856.
11. Brooks DP, Contino LC, Short BG, Gowan C, Trizna W, Edwards RM. SB 203220 : A novel angiotensin II receptor antagonist and renoprotective agent. J Pharmacol Experiment Ther 1995; 274: 1222-7.
12. Nemoto ST, Uda S, Iwasaki S, Iduera T. Angiotensin II (angiotensine II) receptor antagonist suppressed initial mesangiolysis, macrophage infiltration and glomerular endothelial cell proliferation in rats with mesangial proliferate nephritis (abstract). J Am Soc Nephrol 1996; 7: 1734.
13. Kohzuki M, Yasujima M, Kanazawa M et al. Antihypertensive and renal protective effects of Losartan in streptozotocin diabetic rats. J Hypertens 1995; 13: 97-103.
14. Inada Y, Wada T, Ojima M et al. Protectives effects of candesartan cilexetil (TCV-116) against stroke kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1997; 19: 1079-99.
15. Nakamura T, Obata J, Ohno S, Yoshida Y, Kawachi H, Shimizu F. Blocking angiotensin II reduces proteinuria, glomerulosclerosis, glomerular expression of transforming growth factor-b and type I and III collagens in rat progressive mesangioproliferative glomerulonephritis (abstract). J Am Soc Nephrol 1996; 7: 1741.
16. Kawabata M, Takabatake T, Ohta H et al. Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension. Blood Pressure 1994; 3 (suppl. 5): 117-21.
17. Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 1996; 49: 1787-90.
18. Forsblom C, Trenkwalder P, Dahl K, Mulder H. Candesartan Cilexetil, a novel angiotensin II antagonist reduces microalbuminuria in patients with type II diabetes mellitus and mild hypertension (abstract). Diabetologia 1997; 40: A 366.
19. Pohl M, Cooper M, Ulrey J, Pauls J, Rohde R. Safety and efficacy of Irbesartan in hypertensive patients with type II diabetes and proteinuria.(abstract). Am J Hypertension 1994; 10: 4-9.
20. Nielsen S, Dollerup J, Mogensen CE. Losartan reduces albuminuria in patients with essential hypertension, an enalapril controlled 3 months study.(abstract). J Am Soc Nephrol 1995; 5: 646.
21. Gansevoort RT, De Zeeuw D, De Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861-7.
22. Kohzuki M, Tasujima M, Kanazawa M et al. Antihypertensive and renal protective effects of Losartan in streptozotocin diabetic rats. J Hypertens 1995; 13: 97-103.
23. MacKenzie HS, Troy JL, Brenner BM. Effects of combination therapy with Enalapril (Enal) and Losartan (Los) on the rate of progression of experimental renal injury in rats (abstract). J Am Soc Nephrol 1996; 6: 1860.
24. Zoja C, Coma D, Facchineti D et al. Combining ACE inhibition and angiotensin II receptor blocking stop renal disease progression in experimental membranous nephropathy (abstract). J Am Soc Nephrol 1996; 6 (3): 860.
25. Zoccali C, Valvo E, Russo D, Panichi V, Zuccala A. Antiproteinuric effect of Losartan in patients with chronic diseases. Nephrol Dial Transpl 1996; 6: 234-5.
26. Ruilope LM, Aldigier C, Ponticelli P, Oddou-Stock P, Botteri F, Mann JF. Safety of the combination of Valsartan (V) and Benazepril (BZ) in patients with chronic renal disease (CRD) (abstract). J Am Soc Nephrol 1997; 8: 75A.